{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:33:20Z","timestamp":1787740400575,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023630","name":"Faculty of Information Technology, Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1159579"],"award-info":[{"award-number":["GNT1159579"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1184428"],"award-info":[{"award-number":["GNT1184428"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijantimicag.2025.107528","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:31:16Z","timestamp":1746239476000},"page":"107528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of different resistance mechanisms on bacterial response to meropenem, ciprofloxacin, and their combination described by next-generation mechanism-based modelling"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2605-1782","authenticated-orcid":false,"given":"Alice E.","family":"Terrill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-6197","authenticated-orcid":false,"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8031-9086","authenticated-orcid":false,"given":"Jiangning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8590","authenticated-orcid":false,"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4743","authenticated-orcid":false,"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107528_bib0001","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/AAC.45.2.480-484.2001","article-title":"Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates","volume":"45","author":"Pai","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.43.2.424","article-title":"Pechere J.L. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems","volume":"43","author":"K\u00f6hler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0003","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/JB.184.15.4308-4312.2002","article-title":"The MexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity","volume":"184","author":"Adewoye","year":"2002","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0004","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0005","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/S2666-5247(22)00121-5","article-title":"Research priorities towards precision antibiotic therapy to improve patient care","volume":"22","author":"Bulman","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0006","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/antibiotics12040781","article-title":"Clinical diagnostics of bacterial infections and their resistance to antibiotics \u2013 current State and whole genome sequencing implementation perspectives","volume":"12","author":"Avershina","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01150-18","article-title":"Meropenem combined with Ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients","volume":"62","author":"Rees","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0008","doi-asserted-by":"crossref","first-page":"105367","DOI":"10.1016\/j.ebiom.2024.105367","article-title":"Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples","volume":"108","author":"Cortes-Lara","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106616","article-title":"Pharmacokinetic\/pharmacodynamic models for time courses of antibiotic effects","volume":"60","author":"Minichmayr","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0034","series-title":"CLSI M100-Ed34: performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000353","article-title":"Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein","volume":"5","author":"Moya","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0036","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/jac\/dkr232","article-title":"Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem","volume":"66","author":"Riera","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0038","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0039","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.25952","article-title":"Hakki Ciftci I. Investigation of OprD porin protein levels in carbapenem-resistant Pseudomonas aeruginosa isolates","volume":"8","author":"Agah Terzi","year":"2015","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0042","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3947\/ic.2015.47.2.98","article-title":"Spread of efflux pump overexpressing-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa by using an efflux pump inhibitor","volume":"47","author":"Adabi","year":"2015","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0011","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1128\/AAC.04379-14","article-title":"Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii","volume":"59","author":"Yadav","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02055-17","article-title":"Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-Fiber infection model","volume":"62","author":"Landersdorfer","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0013","doi-asserted-by":"crossref","first-page":"e01679","DOI":"10.1128\/AAC.01679-19","article-title":"Meropenem-tobramycin combination regimens combat carbapenem-resistant Pseudomonas aeruginosa in the hollow-fiber infection model simulating augmented renal clearance in critically ill patients","volume":"64","author":"Yadav","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01399-23","article-title":"Comprehensive stability analysis of 13 \u03b2-lactams and \u03b2-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation","volume":"68","author":"Zhou","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0015","first-page":"872","article-title":"Thermal stability assessment of antibiotics in moderate temperature and subcritical water using a pressurized dynamic flow-through system","volume":"11","author":"Svahn","year":"2015","journal-title":"Int J Innov Appl Stud"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0016","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cmi.2024.06.026","article-title":"The effects of single and multiple resistance mechanisms on bacterial response to meropenem","volume":"30","author":"Fuhs","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0017","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/pharmaceutics11090470","article-title":"Evaluation of tobramycin and ciprofloxacin as a synergistic combination against hypermutable Pseudomonas aeruginosa strains via mechanism-based modelling","volume":"11","author":"Rees","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0018","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cmi.2021.05.011","article-title":"GEMARA-SEIMC\/REIPI Pseudomonas study Group. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis","volume":"27","author":"Cortes-Lara","year":"2021","journal-title":"Clini Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0019","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1128\/AAC.00881-09","article-title":"Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model","volume":"54","author":"Bulitta","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0020","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/cpt.2191","article-title":"Evaluation of meropenem-ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance","volume":"109","author":"Agyeman","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0021","doi-asserted-by":"crossref","first-page":"e03189","DOI":"10.1128\/mBio.03189-19","article-title":"Novel cassette assay to quantify the outer membrane permeability of five \u03b2-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae","volume":"11","author":"Kim","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0022","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s101560050028","article-title":"Estimation of outer membrane permeability of carbapenem antibiotics to Pseudomonas aeruginosa","volume":"5","author":"Iyobe","year":"1999","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0023","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/AAC.00092-13","article-title":"Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design","volume":"57","author":"Landersdorfer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0024","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11908-010-0128-x","article-title":"Early antimicrobial therapy in severe sepsis and septic shock","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","article-title":"The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for \u03b2-lactam administration and therapeutic drug monitoring among critically ill patients in France","volume":"22","author":"Charmillon","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0026","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","article-title":"Impact of \u03b2-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy","volume":"49","author":"Economou","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0028","doi-asserted-by":"crossref","first-page":"106269","DOI":"10.1016\/j.ijantimicag.2020.106269","article-title":"Combatting the rising tide of antimicrobial resistance: pharmacokinetic\/pharmacodynamic dosing strategies for maximal precision","volume":"57","author":"Chua","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00414-23","article-title":"Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and heteroresistance","volume":"67","author":"Tait","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2017.12.019","article-title":"Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin\/tazobactam against Pseudomonas aeruginosa and Escherichia coli","volume":"91","author":"Bergen","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0031","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107528_bib0033","doi-asserted-by":"crossref","first-page":"e02307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:40:49Z","timestamp":1762321249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0924857925000858"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107528","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of different resistance mechanisms on bacterial response to meropenem, ciprofloxacin, and their combination described by next-generation mechanism-based modelling","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107528"}}